Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment Highlighting Continued Execution and Strategic Growth

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) published a new CEO Corner segment on Nov 26, 2025.

In the segment, President and CEO Brad Hauser discussed two priorities: protecting the company’s platform via intellectual property, and exploring expansion beyond its initial pancreatic cancer focus into potential cardiovascular, pulmonary, and chronic pain targets.

The segment is available on the company website for investors and stakeholders seeking management commentary on strategy and pipeline direction.

THE WOODLANDS, TX, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the next CEO Corner segment has been published on the Company’s website. For the segment, Brad Hauser, President and CEO of Autonomix, discussed two key areas that are shaping the Company’s path forward: protecting the strength of its platform through intellectual property, and exploring new opportunities beyond its initial target, pancreatic cancer, into potential future targets in the cardiovascular space, pulmonary space as well as chronic pain.

The CEO Corner segment is now available here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com

FAQ

What did Autonomix (AMIX) announce in the CEO Corner on Nov 26, 2025?

Autonomix published a CEO Corner where CEO Brad Hauser discussed strengthening intellectual property and exploring new targets beyond pancreatic cancer.

Where can investors watch the Autonomix (AMIX) CEO Corner segment published Nov 26, 2025?

The CEO Corner segment is available on Autonomix’s corporate website via the investor or news section.

Which new therapeutic areas did Autonomix (AMIX) mention exploring in the Nov 26, 2025 CEO Corner?

The company said it is exploring potential targets in the cardiovascular, pulmonary, and chronic pain areas.

Did Autonomix (AMIX) provide financial guidance or clinical data in the Nov 26, 2025 CEO Corner?

No; the CEO Corner focused on strategy and intellectual property protections and did not include financial guidance or clinical data.

Who spoke in the Autonomix (AMIX) CEO Corner released Nov 26, 2025?

The segment features comments from Brad Hauser, President and CEO of Autonomix.

What is the strategic purpose of the CEO Corner for Autonomix (AMIX) investors?

The CEO Corner provides management commentary on strategy, IP protection plans, and potential expansion into new therapeutic areas to inform investors.